A5058164613- CAR-T cell therapy research
- Virus-based gene therapy research
- Cancer Research and Treatments
- Urological Disorders and Treatments
- Bladder and Urothelial Cancer Treatments
- Blood Pressure and Hypertension Studies
- Biosimilars and Bioanalytical Methods
- Cancer Immunotherapy and Biomarkers
- Nutritional Studies and Diet
- Sodium Intake and Health
- Electrolyte and hormonal disorders
- Viral gastroenteritis research and epidemiology
- Nanowire Synthesis and Applications
- Animal Virus Infections Studies
- Biomedical Ethics and Regulation
- Adenosine and Purinergic Signaling
- Renal function and acid-base balance
- Head and Neck Cancer Studies
- Glioma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- CRISPR and Genetic Engineering
- Urinary and Genital Oncology Studies
- Ubiquitin and proteasome pathways
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
Bexon Clinical Consulting (United States)
2020-2024
Bone Therapeutics
2021
Bayer (United States)
2020
Charité - Universitätsmedizin Berlin
2011-2012
Summary Dabigatran, a specific, reversible direct thrombin inhibitor, is used to prevent ischaemic and haemorrhagic strokes in patients with atrial fibrillation. As every anticoagulant, there need rapidly reverse its effects emergency situations. In an open-label, single-centre phase I study two fixed multiple dosing periods, we investigated the pharmacokinetics, pharmacodynamics safety of dabigatran before, during after 4 hour haemodialysis sessions either 200 or 400 ml/min targeted blood...
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, could be a promising treatment target. We report dose escalation results from the ongoing phase 1/2 BNT211-01 trial evaluating safety feasibility of chimeric receptor (CAR) T cells targeting CLDN6 with or without CAR-T cell-amplifying RNA vaccine (CARVac) at two levels (DLs) relapsed/refractory CLDN6-positive tumors. primary endpoints were tolerability, maximum tolerated recommended 2 (RP2D)....
Abstract Background: BNT211 comprises two drug products, a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific claudin 6 (CLDN6) and CAR-T cell-Amplifying RNA Vaccine (CARVac). In mice, CARVac mediates expansion of adoptively transferred cells, improving their persistence functionality. aims to establish therapy for CLDN6-positive solid tumors. Methods: This first-in-human, open label, multi-center trial involves bifurcated 3+3 design with CLDN6 dose...
Casein-derived tripeptides isoleucine-proline-proline (Ile-Pro-Pro) and valine-proline-proline (Val-Pro-Pro) lower blood pressure (BP) in long-term clinical studies. Their acute effects on BP vascular function, important for daily dosing scheme, were studied a placebo-controlled double-blind crossover study using single oral dose of fermented milk product containing Ile-Pro-Pro Val-Pro-Pro as well plant sterols. Twenty-five subjects with untreated mild hypertension received random order 250...
2518 Background: We are developing a chimeric antigen receptor (CAR)-T cell therapy targeting claudin 6 (CLDN6), an oncofetal that is undetectable in healthy somatic tissue and highly expressed various solid cancers. Autologous CLDN6 CAR-T cells being tested alone combination with CLDN6-encoding Amplifying RNA Vaccine (CARVac), nanoparticulate vaccine designed to stimulate expand cells. Methods: The ongoing first-in-human trial BNT211-01 evaluates the safety feasibility of transfer ± CARVac...
<h3>Background</h3> BNT211 is a chimeric antigen receptor (CAR)-T cell product candidate that targets the tumor specific Claudin-6 (CLDN6). Preclinical studies demonstrated combining these engineered cells with CAR-T Amplifying RNA Vaccine (CARVac) leads to in vivo expansion of adoptively transferred cells, resulting their improved persistence and functionality. <h3>Methods</h3> This first-in-human, open label, multi-center trial involves bifurcated 3+3 design separate CLDN6 dose escalations...
2562 Background: Tumors produce high levels of extracellular adenosine which suppress anti-tumor immune responses. Blocking A 2A receptors, predominantly expressed on tumor-infiltrating cells, can reverse the immunosuppressive effect adenosine. Inupadenant is a non brain-penetrant, potent and highly selective small molecule antagonist receptor that remains active even at concentrations found in tumors. Methods: This phase I portion an ongoing first-in-human, clinical trial (NCT02740985) to...
3090 Background: VV1 (Voyager V1) is derived from VSV, an RNA virus with low human seroprevalence, engineered to replicate selectively in and kill cancer cells. In Part 1 of this study, we demonstrated the safety intratumoral dose-response, using serum IFNβ as a biomarker; observed viral replication tumor concomitant lymphocyte/neutrophil trafficking (SITC 2018). 2 other studies suggested greater efficacy higher levels IV administration. Longer infusion durations were reported mitigate...
The aim of this study was to compare the single-dose effects thiazide-type diuretics cicletanine and hydrochlorothiazide (HCTZ), on natriuresis kaliuresis in prehypertensive treatment-naïve, stage 1 hypertensive patients explore impact GRK4 gene polymorphisms thiazide-induced urinary electrolyte excretion.The a randomized, double-blind, placebo-controlled, three-period, four-treatment, balanced incomplete block, cross-over male assigned treatment sequences consisting placebo, 50 mg, 150 HCTZ...
509 Background: Bladder cancer is a leading cause of death in the United States. The histology > 90% cases urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current standard care for patients with high risk NMIBC includes transurethral resection bladder tumor (TURBT) followed by intravesical immunotherapy Bacillus Calmette-Guerin (BCG). Meanwhile, BCG unresponsive MIBC are recommended to undergo radical cystectomy (RC),...
<h3>Background</h3> Only a minority of patients (20%) with Human Papillomavirus (HPV) 16-positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) responds to first-line (1L) monotherapy pembrolizumab, no approved therapies exist targeting HPV+ disease specifically. Eseba-vec (previously known as HB-200) utilizes arenavirus vectors induce potent HPV-16 E6 E7-specific CD8 T-cell responses. Previously, we reported compelling clinical activity eseba-vec alone in...
Abstract BACKGROUND C/EBPβ is a transcription factor that active during embryofetal development but held in an inactive state most mature cells (Zahnow 2009). activates proliferation/survival gene signature multiple cancers, where it inversely correlates with disease prognosis and survival. ST101 cell-penetrating peptide antagonist of C/EBPβ. exposure leads to selective tumor cell death human cancer lines, including GBM, without impacting normal viability. In vivo, displays rapid uptake into...
TPS3161 Background: VV1 is an oncolytic vesicular stomatitis virus engineered to express human IFNβ enhance cellular anti-tumor immune responses and tumor selectivity, the sodium iodide symporter (NIS) for tracking by SPECT imaging. Cancer cells are often hyporesponsive IFNβ, enabling efficient spread of resulting in increased oncolysis. Differently from other viruses, suitable both intra-tumoral (IT) and/or intra-venous (IV) administration. Despite considerable activity with checkpoint...
<h3>Background</h3> Oncolytic viruses (OVs) show significant potential for treating tumors alongside immunotherapies.<sup>1</sup> VV1 is an OV derived from the innocuous vesicular stomatitis virus (VSV). has been engineered to expresses human interferon (IFN) β and thyroidal sodium iodide symporter (NIS).<sup>2</sup> VV1-infected cells produce IFNβ, which protects non-cancer allows spread more efficiently in cancerous tissue.<sup>3 4</sup> NIS expression on imports 99mTc pertechnetate,...
<h3>Background</h3> Bladder cancer is a leading cause of death in the United States.<sup>1</sup> The histology > 90% cases urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current standard care for patients with high risk NMIBC includes transurethral resection bladder tumor (TURBT) followed by intravesical immunotherapy Bacillus Calmette-Guerin (BCG).<sup>2</sup> Meanwhile, BCG unresponsive MIBC are recommended to...
Abstract Background: Bladder cancer is a leading cause of death in the United States1. The histology &gt; 90% cases urothelial carcinoma (UC). Tumors may present either as non-muscle-invasive (NMIBC) or muscle-invasive disease (MIBC). Current standard care for patients with high risk NMIBC includes transurethral resection bladder tumor (TURBT) followed by intravesical immunotherapy Bacillus Calmette-Guerin (BCG)2. Meanwhile, BCG unresponsive MIBC are recommended to undergo radical...